The purpose of the Office of Human Research Services (OHRS) is to enable and enhance clinical and translational research across the consortium by providing Rutgers Cancer Institute of New Jersey (CINJ) members with centralized resources, information and expertise in clinical research. OHRS has the responsibility of working with clinical investigators to manage the business, clinical and regulatory functions of all phases of pediatric and adult interventional/non-interventional trials at CINJ. The current organizational structure is comprised of approximately 70 FTEs and six functional offices including clinical operations, quality assurance, and regulatory affairs. The activity and use of OHRS parallels the growth of the center and has increased as the number of CINJ investigators and oncology faculty increased. In the most recent grant period (2011-2017) the OHRS managed enrollment of 26,432 patients, compared to the seven-year interval corresponding to the previous grant period (2004-2010) in which 11,454 patients were enrolled. Currently, there are 154 active enrolling trials (92 therapeutic) supported by the OHRS. Given an overall Center initiative to enhance translation of center science, OHRS has increased its support for investigator-initiated and multi-center trials and continues to be used extensively by CINJ members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA072720-20
Application #
9632911
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
20
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212
Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23
Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3
CeliĆ -Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005
George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821
Jian-Yu E; Graber, Judith M; Lu, Shou-En et al. (2018) Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 25:2595-2607
Moloughney, Joseph G; Vega-Cotto, Nicole M; Liu, Sharon et al. (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem 293:16464-16478
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890

Showing the most recent 10 out of 775 publications